R.J. Reynolds Vapor Company, a subsidiary of British American Tobacco (BAT), has acquired 12 synthetic nicotine disposable e-cigarette products from Charlie’s Holdings, Inc. in a transaction valued at up to $9.2 million.
The agreement, finalized on April 16 and disclosed via a Form 8-K filing with the U.S. Securities and Exchange Commission the following day, includes a $5 million upfront payment and a potential earn-out of $4.2 million tied to first-year sales performance.
The acquired assets, marketed under the PACHA brand, were originally submitted to the U.S. Food and Drug Administration in 2022 for review under the agency’s premarket tobacco product application (PMTA) pathway. All 12 products fall within the disposable e-cigarette category and utilize synthetic nicotine formulations. The current regulatory status of the applications has not been publicly disclosed.
The transaction is seen as a strategic move by BAT to bolster its portfolio of products undergoing FDA scrutiny—a critical step as the company positions itself in the evolving and tightly regulated U.S. nicotine landscape.
For Charlie’s Holdings, the sale represents a monetization of assets still awaiting regulatory clearance, potentially providing the company with greater operational flexibility or resources for reinvestment.
Investor response to the deal was swift. Shares of Charlie’s Holdings (CHUC) jumped 33.33% on April 17, closing at $0.10—its highest mark in nearly two months. Analysts interpreted the market reaction as a sign of investor optimism over the company’s ability to extract value from regulatory-stage assets amid growing uncertainty in the nicotine sector.
The agreement includes standard terms such as representations, warranties, and indemnities, and was filed as Exhibit 10.1 to the company’s SEC disclosure.
Industry observers suggest that as FDA regulations continue to reshape the competitive landscape, more companies may look to offload or acquire products that have cleared—or are navigating—the PMTA process. Regulatory-stage assets, particularly those involving synthetic nicotine, are increasingly viewed as high-value plays in a market where compliance is becoming a key differentiator.
